摘要
近年来我国食管癌发病率呈逐渐上升趋势,其死亡率居恶性肿瘤相关死亡第4位。手术是治疗局限病灶患者的主要方式,肿瘤完全切除(R0)失败、病灶的远处扩散或转移是预后不良的主要因素。鉴于单纯手术无法获得较为满意的切除率及预后,在过去10年中联合术前化疗、术前放疗、术前放化疗以及术前靶向治疗的新辅助治疗模式在临床上受到了广泛关注。本综述旨在探讨目前食管癌新辅助治疗的模式及其进展。
The incidence of esophageal cancer shows an increasing trend in recent years, ranking the fourth out of leading causes of cancer-related death in China. Surgery remains the main treatment option for patients with limited lesions, while failure of RO resection and distant metastasis or spread are the predictors of poor prognosis. Over the past decade, due to a low satisfactory removal rate and poor prognosis in treatment of esophageal cancer, an extensive focus has been paid on neoadjuvant therapy, including preoperative chemotherapy, preoperative radiotherapy and preoperative targeted therapy. This paper aims at discussing the current modality and progress of esophageal cancer with neoadjuvant therapy.
作者
屈怡帆
白莉
李娟
李昕雨
QU Yifan BAI Li LI Juan LI Xinyu(Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China)
出处
《解放军医学院学报》
CAS
2016年第11期1214-1216,共3页
Academic Journal of Chinese PLA Medical School
基金
部委级资助项目
军队十二五重大新药创制专项(2012ZX09101103)~~
关键词
食管癌
新辅助化疗
新辅助放疗
三联疗法
手术
esophageal cancer
neoadjuvant chemotherapy
neoadjuvant radiotherapy
trimodal therapy
surgery
